T2	Disease_disorder 168 170	MI
E1	Disease_disorder:T2 
T3	Detail_Description 162 167	acute
R1	MODIFY Arg1:T3 Arg2:E1	
T4	Gender 36 42	female
T5	Age 24 35	54-year-old
T1	Disease_disorder 107 109	HF
E2	Disease_disorder:T1 
T6	Date 137 156	three years earlier
E3	Date:T6 
T7	Diagnostic_procedure 184 204	coronary angiography
E4	Diagnostic_procedure:T7 
T10	Diagnostic_procedure 356 377	coronary intervention
E5	Diagnostic_procedure:T10 
T8	Activity 47 55	admitted
E6	Activity:T8 
T11	Other_entity 115 130	medical history
T12	Anatomical_structure 229 250	right coronary artery
T13	Duration 379 401	During hospitalisation
E7	Duration:T13 
T14	Disease_disorder 408 410	MI
E8	Disease_disorder:T14 
T15	Qualitative_concept 206 221	total occlusion
R2	MODIFY Arg1:T15 Arg2:T12	
T16	Anatomical_structure 288 319	left descending coronary artery
T17	Qualitative_concept 256 278	collateral circulation
R3	MODIFY Arg1:T17 Arg2:T16	
T19	Severity 456 465	Class III
T20	Other_entity 483 531	New York Heart Association (NYHA) classification
T21	Activity 80 89	diagnosis
E9	Activity:T21 
T22	Activity 94 103	treatment
E10	Activity:T22 
T23	Activity 415 424	diagnosed
E11	Activity:T23 
T24	Activity 442 452	classified
E12	Activity:T24 
T25	Lab 583 622	Nterminal-pro-brain natriuretic peptide
E13	Lab:T25 
T26	Qualitative_concept 565 579	elevated level
R6	MODIFY Arg1:T26 Arg2:E13	
T27	Lab 624 633	NT-proBNP
E14	Lab:T27 
T28	Quantitative_concept 635 646	10581 pg/mL
R7	MODIFY Arg1:T28 Arg2:E14	
T29	Sign_symptom 649 668	cardiac enlargement
E15	Sign_symptom:T29 
T30	Lab 728 733	LVEDD
E16	Lab:T30 
T31	Quantitative_concept 735 740	81 mm
R8	MODIFY Arg1:T31 Arg2:E16	
T32	Lab 687 726	left ventricular end-diastolic diameter
E17	Lab:T32 
T33	Qualitative_concept 677 686	increased
R9	MODIFY Arg1:T33 Arg2:E17	
T34	Lab 747 781	left ventricular ejection fraction
E18	Lab:T34 
T35	Qualitative_concept 743 746	low
R10	MODIFY Arg1:T35 Arg2:E18	
T36	Lab 783 787	LVEF
E19	Lab:T36 
T37	Quantitative_concept 789 792	25%
R11	MODIFY Arg1:T37 Arg2:E19	
T40	Location 815 861	inferior, inferoseptal and inferolateral walls
T41	Duration 931 941	Since then
E20	Duration:T41 
T42	Activity 964 971	treated
E21	Activity:T42 
T43	Disease_disorder 976 979	CAD
E22	Disease_disorder:T43 
T44	Disease_disorder 996 1017	arterial hypertension
E23	Disease_disorder:T44 
T45	Disease_disorder 1019 1040	hypercholesterolaemia
E24	Disease_disorder:T45 
T46	Disease_disorder 1042 1064	ventricular arrhythmia
E25	Disease_disorder:T46 
T47	Medication 1066 1076	carvedilol
E26	Medication:T47 
T48	Medication 1078 1086	ramipril
E27	Medication:T48 
T49	Medication 1088 1102	spironolactone
E28	Medication:T49 
T50	Medication 1104 1114	furosemide
E29	Medication:T50 
T51	Medication 1116 1128	atorvastatin
E30	Medication:T51 
T52	Medication 1130 1143	trimetazidine
E31	Medication:T52 
T53	Medication 1145 1152	aspirin
E32	Medication:T53 
T54	Date 1155 1171	Two months later
E33	Date:T54 
T55	Duration 1173 1209	during her admission to our hospital
E34	Duration:T55 
T56	Severity 1240 1253	NYHA class II
T57	Lab 1255 1264	NT-proBNP
E35	Lab:T57 
T58	Quantitative_concept 1265 1275	1869 pg/mL
R14	MODIFY Arg1:T58 Arg2:E35	
T59	Sign_symptom 1211 1225	all parameters
E36	Sign_symptom:T59 
T60	Qualitative_concept 1230 1238	improved
R15	MODIFY Arg1:T60 Arg2:E36	
T61	Lab 1277 1282	LVEDD
E37	Lab:T61 
T62	Quantitative_concept 1283 1288	73 mm
R16	MODIFY Arg1:T62 Arg2:E37	
T63	Lab 1290 1294	LVEF
E38	Lab:T63 
T64	Quantitative_concept 1295 1298	35%
R17	MODIFY Arg1:T64 Arg2:E38	
T65	Disease_disorder 1336 1344	akinesis
E39	Disease_disorder:T65 
T66	Location 1304 1335	inferior and inferolateral wall
T38	Disease_disorder 799 807	akinesis
E40	Disease_disorder:T38 
T39	Disease_disorder 881 892	hypokinesis
E41	Disease_disorder:T39 
T67	Qualitative_concept 867 880	severe global
R13	MODIFY Arg1:T67 Arg2:E41	
T68	Location 896 929	other walls of the left ventricle
T69	Disease_disorder 1358 1369	hypokinesis
E42	Disease_disorder:T69 
T70	Qualitative_concept 1349 1357	moderate
R20	MODIFY Arg1:T70 Arg2:E42	
T71	Location 1373 1384	other walls
T72	Diagnostic_procedure 1387 1426	Cardiovascular magnetic resonance (CMR)
E43	Diagnostic_procedure:T72 
T73	Activity 4062 4071	follow-up
E44	Activity:T73 
T74	Qualitative_concept 4076 4086	uneventful
R22	MODIFY Arg1:T74 Arg2:E44	
T75	Qualitative_concept 4053 4061	two-year
R23	MODIFY Arg1:T75 Arg2:E44	
T76	Result_outcome 4013 4047	No adverse drug reactions occurred
T77	Date 3753 3769	After six months
E45	Date:T77 
T78	Medication 3788 3800	interferon-β
E46	Medication:T78 
T79	Severity 3842 3854	NYHA class I
T80	Lab 3856 3865	NT-proBNP
E47	Lab:T80 
T81	Quantitative_concept 3866 3875	512 pg/mL
R24	MODIFY Arg1:T81 Arg2:E47	
T82	Lab 3877 3882	LVEDD
E48	Lab:T82 
T83	Quantitative_concept 3883 3888	68 mm
R25	MODIFY Arg1:T83 Arg2:E48	
T84	Lab 3890 3894	LVEF
E49	Lab:T84 
T85	Quantitative_concept 3895 3898	45%
R26	MODIFY Arg1:T85 Arg2:E49	
T86	Severity 3818 3840	improved significantly
T87	Duration 3647 3676	fourth month of the treatment
E50	Duration:T87 
T88	Other_entity 1604 1643	no history of recent infection or fever
T89	Lab 1462 1495	late gadolinium enhancement (LGE)
E51	Lab:T89 
T90	Location 1503 1591	inferoseptal (mid-wall), inferior (sub-endocardial) and inferolateral (transmural) walls
T92	Location 1731 1762	inferoseptal and inferior walls
T93	Diagnostic_procedure 2938 2958	coronary angiography
E53	Diagnostic_procedure:T93 
T94	Diagnostic_procedure 2991 3011	previous examination
E54	Diagnostic_procedure:T94 
T95	Diagnostic_procedure 3233 3274	Examination of frozen specimens with qPCR
E55	Diagnostic_procedure:T95 
T96	Diagnostic_procedure 3678 3681	EMB
E56	Diagnostic_procedure:T96 
T97	Sign_symptom 3700 3751	no HEV RNA was detected in the heart tissue samples
E57	Sign_symptom:T97 
T98	Diagnostic_procedure 1853 1869	Echocardiography
E58	Diagnostic_procedure:T98 
T99	Diagnostic_procedure 2069 2096	endomyocardial biopsy (EMB)
E59	Diagnostic_procedure:T99 
T100	Diagnostic_procedure 2330 2364	Electron microscopy of EMB samples
E60	Diagnostic_procedure:T100 
T101	Diagnostic_procedure 2111 2114	EMB
E61	Diagnostic_procedure:T101 
T102	Activity 2115 2144	did not confirm the suspicion
E62	Activity:T102 
T103	Therapeutic_procedure 2564 2584	HF and CAD treatment
E63	Therapeutic_procedure:T103 
T104	Activity 2589 2601	administered
E64	Activity:T104 
T105	Administration 2619 2667	guidelines of the European Society of Cardiology
T9	Activity 334 351	had not undergone
E65	Activity:T9 
T18	Other_entity 59 71	our hospital
T106	Date 2678 2696	three months later
E66	Date:T106 
T107	Activity 2713 2727	rehospitalised
E67	Activity:T107 
T108	Complication 2739 2754	HF exacerbation
T109	Severity 2756 2770	NYHA Class III
T110	Quantitative_concept 2782 2792	1980 pg/dL
T111	Lab 2772 2781	NT-proBNP
E68	Lab:T111 
T112	Lab 2794 2802	troponin
E69	Lab:T112 
T113	Quantitative_concept 2803 2810	3 ng/mL
T114	Lab 2812 2817	LVEDD
E70	Lab:T114 
T115	Quantitative_concept 2818 2823	77 mm
T116	Lab 2825 2829	LVEF
E71	Lab:T116 
T117	Quantitative_concept 2830 2833	30%
T118	Diagnostic_procedure 2891 2920	24-hour Holter ECG monitoring
E72	Diagnostic_procedure:T118 
T119	Sign_symptom 2840 2865	ventricular extrasystoles
E73	Sign_symptom:T119 
T120	Quantitative_concept 2835 2839	8048
R4	MODIFY Arg1:T120 Arg2:E73	
R5	MODIFY Arg1:T117 Arg2:E71	
R12	MODIFY Arg1:T115 Arg2:E70	
R18	MODIFY Arg1:T113 Arg2:E69	
R19	MODIFY Arg1:T110 Arg2:E68	
T121	Qualitative_concept 2866 2887	without complex forms
R21	MODIFY Arg1:T121 Arg2:E73	
T122	Anatomical_structure 2520 2533	blood vessels
T123	Other_entity 2435 2445	myofibrils
T124	Other_entity 2447 2454	nucleus
T125	Other_entity 2456 2469	mitochondrion
T126	Other_entity 2471 2492	endoplasmic reticulum
T127	Other_entity 2494 2518	intercellular connection
T128	Sign_symptom 2540 2561	no virus was detected
E74	Sign_symptom:T128 
T129	Sign_symptom 2374 2433	ultrastructural changes in all elements of the heart tissue
E75	Sign_symptom:T129 
T130	Other_entity 2165 2327	Dallas (presence of myocytolysis and myocardial fibrosis only) and immunohistochemical criteria (no CD3, CD4, CD8-positive cells, single LCA, CD68-positive cells)
T131	Activity 171 180	confirmed
E76	Activity:T131 
T132	Sign_symptom 1661 1674	LV dilatation
E77	Sign_symptom:T132 
T91	Sign_symptom 1676 1723	a characteristic pattern of LGE for myocarditis
E52	Sign_symptom:T91 
T133	Lab 1827 1837	troponin I
E78	Lab:T133 
T134	Quantitative_concept 1839 1850	0.014 ng/mL
R27	MODIFY Arg1:T134 Arg2:E78	
T135	Qualitative_concept 1775 1823	persistence of a slightly elevated concentration
R28	MODIFY Arg1:T135 Arg2:E78	
T136	Sign_symptom 3984 3987	ExV
E79	Sign_symptom:T136 
T137	Medication 3394 3406	interferon-β
E80	Medication:T137 
T138	Activity 3379 3388	treatment
E81	Activity:T138 
T139	Activity 3773 3782	treatment
E82	Activity:T139 
T140	Activity 2959 2968	resembled
E83	Activity:T140 
T141	Quantitative_concept 3457 3474	62.5 μg (0.25 mL)
T142	Date 3482 3492	first week
E84	Date:T142 
T143	Quantitative_concept 3494 3509	125 μg (0.5 mL)
T144	Date 3517 3539	second and third weeks
E85	Date:T144 
T145	Quantitative_concept 3545 3563	187.5 μg (0.75 mL)
R29	MODIFY Arg1:T141 Arg2:E80	
R30	MODIFY Arg1:T143 Arg2:E80	
R31	MODIFY Arg1:T145 Arg2:E80	
T146	Frequency 3579 3594	every other day
E86	Frequency:T146 
T147	Duration 3595 3636	from the fourth to the twenty-fourth week
E87	Duration:T147 
T148	Administration 3564 3578	subcutaneously
T149	Diagnostic_procedure 3935 3959	24-hour Holter recording
E88	Diagnostic_procedure:T149 
T150	Quantitative_concept 3979 3983	1889
R32	MODIFY Arg1:T150 Arg2:E79	
T151	Qualitative_concept 3989 4010	without complex forms
R33	MODIFY Arg1:T151 Arg2:E79	
T152	Disease_disorder 3313 3333	viral cardiomyopathy
E89	Disease_disorder:T152 
T153	Activity 3338 3347	diagnosed
E90	Activity:T153 
T154	Sign_symptom 3288 3307	presence of HEV RNA
E91	Sign_symptom:T154 
T155	Diagnostic_procedure 3084 3138	real-time polymerase chain reaction examination (qPCR)
E92	Diagnostic_procedure:T155 
A1	POLARITY E62 NEG
T156	Other_entity 2006 2030	suspicion of myocarditis
T157	Other_entity 1885 1896	correlation
T158	Qualitative_concept 1881 1884	low
R34	MODIFY Arg1:T158 Arg2:T157	
T159	Sign_symptom 1909 1932	coronary artery changes
E93	Sign_symptom:T159 
T160	Sign_symptom 1937 1958	cardiac contractility
E94	Sign_symptom:T160 
R35	MODIFY Arg1:T157 Arg2:E93	
R36	MODIFY Arg1:T157 Arg2:E94	
